COMMUNIQUÉS West-GlobeNewswire

Codetta Bio™ Expands Global Commercial Leadership to Accelerate Worldwide Adoption of the Concerto™ System
09/12/2025
DURHAM, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Codetta Bio™, a leading innovator in multi-omic solutions that integrate ultrasensitive protein quantitation with simultaneous analysis of nucleic acids (RNA and DNA), [...]
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science
09/12/2025
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet [...]
ONL Therapeutics Announces Publication of Data from Phase 1b Study of Xelafaslatide, an Investigational Therapy for Geographic Atrophy, in Ophthalmology Science
09/12/2025
Xelafaslatide was safe and well tolerated at all evaluated doses, with the potential to reduce GA lesion growth and improve vision ANN ARBOR, Mich., Dec. 09, 2025 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical- [...]
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
09/12/2025
Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 million, a 40% increase over 2025 1 , and core [...]
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel
09/12/2025
Ms. Ishak brings more than 25 years of corporate legal and strategic leadership experience in the life sciences industry CHATHAM, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP [...]
Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
09/12/2025
Expert panel offers data-driven guidance for integrating DecisionDx-Melanoma into clinical decision-making for patients with melanoma FRIENDSWOOD, Texas, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. ( [...]
Transpire Bio Manufacturing Facility Receives the Establishment Inspection Report Following a Pre-Approval Inspection by the U.S. FDA
09/12/2025
SUNRISE, Fla., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated, clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced [...]
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors
09/12/2025
– City of Hope to Evaluate PEDMARK ® for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors – – Initiation of Study Reflects Growing Clinical Interest in Addressing the Burden of [...]
Lungpacer Achieves Commercial Milestone as Leading U.S. Hospital Performs First AeroPace® Procedures to Help Patients Liberate from Mechanical Ventilation
09/12/2025
AeroPace temporary transvenous diaphragm neurostimulation system now available to help critically ill patients breathe independently faster EXTON, Pa., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Lungpacer Medical , a leader in [...]
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease
09/12/2025
Initial favorable safety profile demonstrated in OPGx-BEST1 clinical trial RESEARCH TRIANGLE PARK, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage [...]
Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia
09/12/2025
RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) based on preliminary clinical evidence, and offers [...]
Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile
09/12/2025
ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of all responses were [...]
Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives
09/12/2025
Continued listing reflects progress on turnaround strategy and pipeline advancement BURLINGTON, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP) (“Abpro” or the “Company”), a biotechnology [...]
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
09/12/2025
Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus chemotherapy in first- [...]
Pow.Bio and Bühler join forces to advance next-generation precision fermentation
09/12/2025
ALAMEDA, Calif. and UZWIL, Switzerland, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Pow.Bio, the pioneer in AI-enabled continuous fermentation technology, and Bühler Group, the global solution provider for food, feed, and [...]
Terns Announces Proposed Public Offering
09/12/2025
FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has commenced a proposed [...]
Osivax Completes Enrollment in Phase 2b Asuniva Trial Evaluating Broad-Spectrum Influenza A Vaccine Candidate OVX836
09/12/2025
Target enrollment of 2,850 healthy volunteers completed across multiple European countries Topline data read-out expected by mid-2026, subject to influenza circulation during the winter season Lyon, France and Liège, [...]
Zelluna ASA: Cancellation of subsequent repair offering
09/12/2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. [...]
Relation announces further $26 million investment
09/12/2025
LONDON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Relation today announced a further $26 million investment from existing investors NVentures (NVIDIA’s venture capital arm) and leading deeptech investors DCVC and Magnetic [...]

Pages